Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of "Hold" from Analysts

Key Points

• Definitive Healthcare Corp. has received a consensus recommendation of "Hold" from six brokerages, with one sell and one buy rating.
• The average one-year target price for the stock is $4.28, with Robert W. Baird setting a price objective of $4.00 and Stifel Nicolaus lifting their target to $6.00.
• Approximately 98.67% of Definitive Healthcare's stock is owned by institutional investors, highlighting significant institutional interest in the company.

Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) has been assigned a consensus recommendation of "Hold" from the six brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $4.28.

DH has been the subject of several analyst reports. Robert W. Baird set a $4.00 price objective on shares of Definitive Healthcare in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Definitive Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Finally, Stifel Nicolaus lifted their price objective on shares of Definitive Healthcare from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Friday, August 8th.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock opened at $4.04 on Tuesday. Definitive Healthcare has a twelve month low of $2.15 and a twelve month high of $5.68. The company has a quick ratio of 1.65, a current ratio of 1.65 and a debt-to-equity ratio of 0.39. The company has a 50-day simple moving average of $3.98 and a two-hundred day simple moving average of $3.50. The stock has a market capitalization of $578.29 million, a price-to-earnings ratio of -1.52 and a beta of 1.65.

Institutional Trading of Definitive Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its stake in Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company's stock worth $25,191,000 after purchasing an additional 7,404,363 shares in the last quarter. Palisade Capital Management LP raised its position in shares of Definitive Healthcare by 1.3% in the 1st quarter. Palisade Capital Management LP now owns 2,265,198 shares of the company's stock valued at $6,546,000 after buying an additional 29,774 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Definitive Healthcare in the 2nd quarter valued at approximately $4,247,000. Whetstone Capital Advisors LLC acquired a new position in shares of Definitive Healthcare in the 1st quarter valued at approximately $2,512,000. Finally, Bank of America Corp DE raised its position in shares of Definitive Healthcare by 23.7% in the 2nd quarter. Bank of America Corp DE now owns 769,397 shares of the company's stock valued at $3,001,000 after buying an additional 147,599 shares in the last quarter. Institutional investors and hedge funds own 98.67% of the company's stock.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.